Company Filing History:
Years Active: 2020-2022
Title: Innovations by Vera Brinks in Epidermolysis Bullosa Therapy
Introduction
Vera Brinks is a notable inventor based in Leiden, Netherlands. She has made significant contributions to the field of medical research, particularly in the development of therapies for epidermolysis bullosa. With a total of 2 patents, her work focuses on innovative solutions that address critical health challenges.
Latest Patents
One of her latest patents involves the creation of oligonucleotides that match COL7A1 exon 73 for epidermolysis bullosa therapy. These antisense oligonucleotides are designed to prevent or reduce the inclusion of exon 73 into the human COL7A mRNA. They are characterized by several features: the oligonucleotide's sequence includes at most two CpG sequences, the length does not exceed 24 nucleotides, and it is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon 73. Additionally, these oligonucleotides can be oligoribonucleotides with modified internucleosidic linkages, such as phosphorothioate linkages.
Career Highlights
Vera Brinks is currently associated with Wings Therapeutics, Inc., where she continues to advance her research and innovations. Her work is pivotal in the ongoing efforts to develop effective treatments for genetic disorders.
Collaborations
She collaborates with esteemed colleagues, including Elisabeth Marlene Haisma and Marko Potman, who contribute to her research endeavors and help drive innovation in the field.
Conclusion
Vera Brinks exemplifies the spirit of innovation in medical research, particularly through her work on therapies for epidermolysis bullosa. Her contributions are vital in the quest for effective treatments for this challenging condition.